Zentalis Pharmaceuticals (ZNTL) Long-Term Investments (2021 - 2024)

Zentalis Pharmaceuticals' Long-Term Investments history runs 4 years deep, the most recent figure standing at $349.9 million for Q3 2024.

• In Q3 2024, Long-Term Investments changed N/A year-over-year to $349.9 million; the TTM figure through Sep 2024 stood at $349.9 million (changed N/A YoY), while the FY2023 annual figure was $454.9 million, up 2044.35% from the prior year.
• Long-Term Investments for Q3 2024 stood at $349.9 million, down from $389.4 million in the prior quarter.
• The five-year high for Long-Term Investments was $454.9 million in Q4 2023, with the low at $18.9 million in Q1 2023.
• The 4-year median for Long-Term Investments is $37.5 million (2021), against an average of $168.8 million.
• The sharpest annual moves came in 2023 and 2024: Long-Term Investments plunged 47.12% in 2023, then jumped 2287.81% in 2024.
• Zentalis Pharmaceuticals' Long-Term Investments stood at $37.5 million in 2021, then tumbled by 43.42% to $21.2 million in 2022, then jumped by 2044.35% to $454.9 million in 2023, then declined by 23.07% to $349.9 million in 2024.
• Business Quant data shows ZNTL's Long-Term Investments at $349.9 million in Q3 2024, $389.4 million in Q2 2024, and $451.4 million in Q1 2024.